title: Phase II evaluation of trans-N3P3Az2(NHMe)4 (AZP) in non-small cell lung cancer.
abstract: Trans-N3P3Az2(NHMe)4 (AZP), an aziridinyl substituted cyclophosphazene, was evaluated in a phase II study in non-small cell lung cancer at a dose of .33 mg/m2 i.v. bolus every 3 weeks. There were no tumor responses seen. Cumulative bone marrow toxicity, comparable to other cyclophosphazenes, was noted. AZP is not useful for the treatment of NSCLC.
authors.affiliation: Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.
authors.forename: P E
authors.initials: PE
authors.lastname: Postmus
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
authors.forename: J C
authors.initials: JC
authors.lastname: Grampel
authors.forename: W H
authors.initials: WH
authors.lastname: Meyers
authors.forename: H H
authors.initials: HH
authors.lastname: Berendsen
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001388:Aziridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; C048802:1,3-diaziridino-2,4,6-triaza-1,3,5,5-tetraaminomethyl-1,3,5-triphosphorin